Clinical trials: Diabetic Macular Edema (DME)
Macular Edema
Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)
To evaluate the efficacy of long-term treatment with 2 mg aflibercept via different intravitreal (IVT) treatment regimens to participants with DME pretreated with 2 mg aflibercept every 8 weeks after 5 initial monthly injections…
- Trial name
- VIOLET (NCT02818998)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- 64 sites in Austria, Canada and 12 more
- Volunteers
- 463 people
- Sponsor
- Bayer
Diabetic Macular Edema (DME)
High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
Patients with diabetic macular edema (DME) sometimes must undergo vitrectomy surgery (PPV) for diabetic and non-diabetic related issues.
- Trial name
- NCT06662994
- Testing
- Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Retina Consultants of Orange County
Diabetic Macular Edema
Evaluation of Tonabersat for DME
This randomized clinical trial will evaluate the effect of tonabersat compared with placebo on central subfield thickness (CST) in eyes with center-involved diabetic macular edema (CI-DME) and good visual acuity.
- Trial name
- AN (NCT05727891)
- Testing
- Tonabersat
- Where
- 28 sites in United States
- Volunteers
- 128 people
- Sponsor
- Jaeb Center for Health Research
Diabetic Macular Edema, Macular Edema
MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema.
- Conditions
- Diabetic Macular Edema, Macular Edema, Type 2 Diabetes With Diabetic Macular Edema, Type 1 Diabetes With Diabetic Macular Edema
- Trial name
- NCT04187443
- Testing
- MS-553
- Where
- 3 sites in China
- Volunteers
- 45 people
- Sponsor
- Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
Diabetic Macular Edema
Evaluation of Bromocriptine, Metoprolol and Tamsulosin in Eyes With Non-Central DME
This phase I/II trial is designed to provide proof of concept evidence that combination therapy can have a beneficial effect on DME and possibly prevent increases in retinal volume or progression of non-central DME into the…
- Trial name
- NCT03384524
- Testing
- Bromocriptine 2.5 MG, Metoprolol 25 MG, Tamsulosin 0.4 MG
- Sponsor
- Andrew Moshfeghi, MD, MBA
Diabetic Macular Edema (DME)
Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-02)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with diabetic macular edema (DME).
- Trial name
- ATACAMA (NCT07841899)
- Testing
- OLN324, Aflibercept
- Volunteers
- 450 people
- Sponsor
- Ollin Biosciences, Inc.
Diabetic Retinopathy (DR), Diabetic Macular Edema (DME)
Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery
Objective of this randomised controlled trial is to compare the efficacy of a single per operative anti VEGF injection with repeated postoperative anti VEGF injections in the prevention of diabetic retinopathy progression after…
- Conditions
- Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Cataract, Phacoemulfisication+IOL Implantation
- Trial name
- NCT07301775
- Testing
- Aflibercept (Eylea)
- Where
- 2 sites in Pakistan
- Volunteers
- 166 people
- Sponsor
- Ahmad Zeeshan Jamil
Diabetic Macular Edema
Efficacy and Safety of Betamethasone Microsphere in Patients With Diabetic Macular Edema (TSUBASA)
This study will evaluate the efficacy and safety of Betamethasone Microsphere (DE-102) for diabetic macular edema.
- Trial name
- NCT01411254
- Testing
- Betamethasone Microsphere (DE-102） Low Dose, Betamethasone Microsphere (DE-102） High Dose
- Where
- Japan
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Diabetic Macular Edema
A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study
CRFB002D2301: The core study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or mono-therapy in patients with visual impairment due to…
- Trial name
- RESTORE (NCT00687804)
- Testing
- Ranibizumab, Laser
- Where
- 13 sites in Australia, Belgium and 11 more
- Volunteers
- 345 people
- Sponsor
- Novartis
Diabetic Macular Edema (DME), Diabetic Retinopathy
Corticosteroid for Diabetic Macular Edema (DME) Study
Our current goals include confirming inflammation mediators are biomarkers of DR and DME The Aim of this project is to measure aqueous PGE2 and inflammatory cytokines before and after treatment of DME with intravitreal…
- Trial name
- NCT07843849
- Testing
- Intravitreal dexamethasone implant
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Diabetic Macular Edema (DME)
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
The purpose of this study is to evaluate the safety and efficacy of AKB-9778 administered as daily subcutaneous injections with and without monthly intravitreal injections of ranibizumab for 3 months in patients with diabetic…
- Trial name
- TIME-2 (NCT02050828)
- Testing
- AKB-9778, ranibizumab
- Where
- 39 sites in United States
- Volunteers
- 144 people
- Sponsor
- Aerpio Therapeutics
Diabetes Mellitus, Diabetic Retinopathy
A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema
Part A of the study is conducted to select the THR-149 dose level. Part B of the study is conducted to assess the efficacy and safety of the selected dose level compared to aflibercept, up to Month 3.
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- KALAHARI (NCT04527107)
- Testing
- THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3
- Where
- 78 sites in United States, Czechia and 6 more
- Volunteers
- 135 people
- Sponsor
- Oxurion
Diabetic Retinopathy
Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME)
A randomized, controlled study of the safety and efficacy of Squalamine Lactate Eye Drops in combination with Ranibizumab intravitreal injections in patients with diabetic macular edema.
- Trial name
- NCT02349516
- Testing
- Squalamine Lactate Ophthalmic Solution 0.2%
- Where
- United States
- Sponsor
- Starr Muscle
Diabetic Macular Edema
DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME
Both aflibercept and bevacizumab have been shown to improve vision in eyes with DME. In eyes with DME and at least moderate vision loss, both aflibercept and bevacizumab were also shown to be successful in many eyes.
- Trial name
- DRCR AC (NCT03321513)
- Testing
- intravitreous aflibercept, Bevacizumab + Deferred Aflibercept Group
- Where
- 54 sites in United States
- Volunteers
- 270 people
- Sponsor
- Jaeb Center for Health Research
Diabetic Macular Edema
Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab
The purpose of this study is to determine the efficacy of intravitreal aflibercept injections administered in a treat and extend fashion in eyes that have persistent center involved diabetic macular edema following at least 4…
- Trial name
- NCT03059277
- Testing
- Intravitreal Aflibercept
- Where
- 2 sites in United States
- Sponsor
- Southeast Clinical Research Associates, LLC
Diabetic Macular Edema
Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)
This is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will be treated for 12 weeks.
- Trial name
- NCT00536692
- Testing
- mecamylamine
- Where
- 3 sites in United States
- Sponsor
- CoMentis
Diabetic Macular Edema
Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study
This study looks to continue the study of anti-vegf therapy in patients with macular edema, and compare it to an anti-inflammatory therapy and a combined Anti-vegf and anti-inflammatory.
- Trial name
- CAPTURE (NCT00676559)
- Testing
- Efalizumab, Ranibizumab
- Where
- 10 sites in United States
- Sponsor
- Johns Hopkins University
Diabetic Macular Edema (DME)
A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial to Evaluate the Safety, Efficacy, and Durability of a Single Intravitreal Injection of 4D-150 versus Aflibercept in Adults with Diabetic Macular Edema (4SIGHT)
- Trial name
- 4SIGHT (NCT07867080)
- Testing
- 4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 92 sites in United States, China and 2 more
- Volunteers
- 514 people
- Sponsor
- 4D Molecular Therapeutics
Diabetic Macular Edema (DME)
Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients
Patients were included in the study who were pseudophakic with center-involved (sub-foveal) diabetic macular edema
- Trial name
- NCT06882551
- Testing
- Intravitreal Bevacizumab IVB, intravitreal bevacizumab and suprachoroidal triamcinolone acetonide
- Where
- Pakistan
- Volunteers
- 82 people
- Sponsor
- Khyber Teaching Hospital
Clinically Significant Diabetic Macular Edema
Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema
The Endurance Trial is a Phase IV open label clinical study to assess the need for ongoing intravitreal aflibercept injections after the 3-year VISTA DME (VGFT-OD-1009) endpoint.
- Trial name
- Endurance3 (NCT02734407)
- Testing
- Assigned Intervention, aflibercept 2.0 mg
- Volunteers
- 9 people
- Sponsor
- Retina-Vitreous Associates Medical Group